Jef­frey Blue­stone brings his start­up haul to $400M+, join­ing forces with Re­gen­eron on cell ther­a­pies

These days, when Jef­frey Blue­stone gets to­geth­er with his con­tem­po­raries in sci­ence, the con­ver­sa­tion of­ten turns to re­tire­ment plans.

But a lit­tle more than three …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN